BUZZ-Zymeworks jumps after JPM upgrades stock to 'overweight'

JPMorgan Upgrades Zymeworks to Overweight From Neutral, Adjusts Price Target to $18 From $12

Zymeworks Inc : Jefferies Raises Target Price to $24 From $22

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Hims & Hers Health (HIMS), Zymeworks (ZYME) and Axsome Therapeutics (AXSM)

Zymeworks Inc : JP Morgan Raises to Overweight From Neutral; Raises Target Price to $18 From $12

U.S. RESEARCH ROUNDUP-Amazon, Broadcom, Exxon Mobil

Zymeworks Advances Oncology and Expands Therapeutic Reach

PRESS DIGEST-Canada - Nov 22

Zymeworks Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

Zymeworks Shares up 2.8% After FDA Approves Co, Jazz Pharma's Biliary Tract Cancer Drug

Zymeworks Shares Rise 8.3% After Licensed Cancer Treatment Gets FDA OK

Zymeworks Inc : Leerink Partners Raises Target Price to $26 From $25

Zymeworks to Showcase Innovations at Investor Conferences

Zymeworks Secures FDA Approval for Ziihera

Zymeworks, Jazz Pharmaceuticals Receive FDA's Accelerated Approval for Ziihera to Treat Biliary Tract Cancer

Zymeworks Shares up 2.5% Premarket After FDA Approves Co, Jazz Pharma's Biliary Tract Cancer Drug

FDA Grants U.S. Approval of Ziihera® (Zanidatamab-Hrii) for the Treatment of Adults With Previously Treated, Unresectable or Metastatic Her2-Positive (Ihc 3+) Biliary Tract Cancer (BTC)

Zymeworks Inc - to Receive $25M Milestone Payment From Jazz Pharmaceuticals

Zymeworks Shares Rise After Upgrade From Leerink Partners